ArticlePloS one2025
Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamics of HIV reservoirs following repeated anti-SARS-CoV-2 vaccination.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaccination was included in the Indonesian government policy to address Delta and Omicron waves of SAR-CoV-2 infections. This study assesses the effectiveness of inactivated (CoronaVac, BBIBP-Cor) and mRNA vaccines (mRNA-1273, BNT162b2) against COVID-19 regardless of symptoms and fatal COVID-19 (mortality within 30 days after confirmed RT-PCR) during Delta and Omicron period in Jakarta, Indonesia.
methodsThis study case-control, test-negative study included all individuals aged over 18 years in Jakarta with complete and consistent SARS-CoV-2 RT-PCR results from 1 June to 31 August 2021 (Delta period) and 1 January to 2 April 2022 (Omicron period), as well as complete vaccination status. This study integrates several public health data from the Jakarta provincial government. From the odds ratio, vaccine effectiveness (VE) was analyzed as the primary outcome using unmatched analysis, matched analysis, and adjustments for other factors.
resultsThis study includes 982,885 eligible subjects recorded from March 2021 to April 2022. All subjects generally underwent testing 4-9 weeks after their last vaccine dose. The VE of 2-dose inactivated vaccine against SARS-CoV-2 infection during Delta wave was 22.06% (95% CI 20.63-24.54) and the VE against fatal COVID-19 was 78.55% (95% CI 72.91-83.00). A complete primary dose of mRNA vaccine showed VE of 24.81% (95% CI 16.81-32.09) against infection during Omicron wave. Furthermore an additional mRNA booster dose showed VE of 68.82% (95% CI 54.11-78.82) based on unmatched analysis.
conclusionA complete primary dose of inactivated vaccine provided mild protection against COVID-19 and essential protection against fatal cases during the Delta wave, but offered little to no protection during the Omicron wave. In contrast, the mRNA vaccine, either as primary vaccination, homologous, or heterologous booster regimen, conferred acceptable protection against Omicron. This study recommends real-world vaccination strategies for LMICs with typical vaccine supply constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.